Atea Pharmaceuticals Inc Environmental Analytics
Environmental and financial analysis dashboard for Atea Pharmaceuticals Inc. Industry: PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES
Company Overview for Atea Pharmaceuticals Inc
Highlights
Showing data for FY2022
Operational Environmental Cost
N/A
Operational Environmental Cost Intensity
N/A
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
N/A
Decoupling Rate (2020-2022)
N/A
Adjusted EBITDA
N/A
Adjusted EBITDA Margin
N/A
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 790.45% | N/A | N/A | ||
| 0.29% | 0.36% | N/A | N/A | |
| 845.44% | N/A | N/A | ||
| 0.56% | 0.73% | N/A | N/A | |
| $0m | $4m | N/A | N/A | |
| 826.61% | N/A | N/A | ||
| 0.85% | 1.09% | N/A | N/A | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
N/A
Adjusted EBIT Margin
N/A
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$49m | $351m | $0m | $0m | |
| 622.54% | -100.00% | 0.00% | ||
$60m | $213m | N/A | N/A | |
| 122.64% | 60.61% | 0.00% | 0.00% | |
$-11m | $138m | N/A | N/A | |
| -22.64% | 39.39% | 0.00% | 0.00% | |
$-11m | $138m | N/A | N/A | |
| -22.68% | 39.38% | 0.00% | 0.00% | |
| ENVIRONMENTAL COST DATA | ||||
$0m | $4m | N/A | N/A | |
| 0.85% | 1.09% | 0.00% | 0.00% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$-11m | $135m | N/A | N/A | |
| -23.49% | 38.31% | 0.00% | 0.00% | |
$-11m | $135m | N/A | N/A | |
| -23.53% | 38.30% | 0.00% | 0.00% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
RESEARCH AND EXPERIMENTAL DEVELOPMENT ON NATURAL SCIENCES AND ENGINEERING
Scope 1 (% of Sales)
N/A
Scope 2 (% of Sales)
N/A
Operational Environmental Cost Intensity
N/A
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
Atea Pharmaceuticals Inc | US | $0m | 0.00% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022